SCYNEXIS (NASDAQ:SCYX) Bolsa, Quote.MetaTitle.unusual-options

SCYNEXIS

Panorámica general

Noticias

Beneficios

Opciones

Calificaciones de analistas

Operaciones de insiders

Interés en corto

Informe de acciones

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Comments

SCYNEXIS Opciones Inusuales

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL